Abstract | BACKGROUND: METHOD: Eleven adolescent patients with ASD (9 boys and 2 girls, aged 12.2 ± 3.6 years) with depressive and ADHD symptoms were treated with reboxetine (maximal dose, 4 mg/d) in an open-label trial during a 12-week period. The severity of depressive and ADHD symptoms was assessed by the Child Depression Rating Scale (CDRS) and Attention-Deficit/Hyperactivity Disorder Rating Scale ( ADHD-RS), respectively. RESULTS: Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and ADHD symptoms ( Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment. The patients (n = 5) with high baseline scores of CDRS (T score >75) showed a trend toward larger response to reboxetine than those (n = 6) with low (T score <75) basal CDRS scores (Δ, 12.8 ± 5.4 vs 2.3 ± 5.2; P = 0.07).A significant positive correlation was found between the changes in the total scores of the depression and the ADHD severity (Spearman correlation r = 0.65 [95% confidence interval, 0.09-0.9]; n = 11; P = 0.029). Most of the patients (approximately 90%) reported tolerable adverse effects. CONCLUSIONS:
Reboxetine treatment may reduce, modestly but significantly, depressive and ADHD symptoms in adolescents with ASD. High rate of adverse effects requires close monitoring.
|
Authors | Pavel Golubchik, Jonathan Sever, Abraham Weizman |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2013 Mar-Apr
Vol. 36
Issue 2
Pg. 37-41
ISSN: 1537-162X [Electronic] United States |
PMID | 23503544
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antidepressive Agents
- Morpholines
- Reboxetine
|
Topics |
- Adolescent
- Adrenergic Uptake Inhibitors
(therapeutic use)
- Antidepressive Agents
(therapeutic use)
- Asperger Syndrome
(drug therapy, epidemiology, psychology)
- Attention Deficit Disorder with Hyperactivity
(drug therapy, epidemiology, psychology)
- Autistic Disorder
(drug therapy, epidemiology, psychology)
- Child
- Depression
(drug therapy, epidemiology, psychology)
- Female
- Humans
- Male
- Morpholines
(therapeutic use)
- Reboxetine
- Treatment Outcome
|